An intravenous programmed death-1 inhibitor to treat advanced treatment-naive melanoma.
Emerging Technology Reports
The Emerging Technology Report provides regular updates about emerging and potentially disruptive technologies that are likely to have a significant impact in healthcare. This “early warning” report monitors new health technologies from 6 months to 2 years within a regulatory submission and tracks those as they go through clinical trial development and the regulatory approval process.
For each emerging technology, our analysts describe the technology and intended use, its prospects relative to the regulatory process and FDA information, competing technologies, relevant clinical guidelines, high-level look at the evidence such as published abstracts in the medical literature and available meeting abstracts, and available clinical trials.
Odalasvir (ACH-3102), ACH-3422, and Sovaprevir (ACH-1625) All-Oral Regimens for Chronic HCV Infection
Investigational direct-acting antivirals for interferon-free combination regimens to treat hepatitis C virus infection.
Galeterone (TOK-001)
A multitargeted oral steroid analog to treat metastatic castration-resistant prostate cancer in patients whose tumors express the AR-V7 splice variant.
LY2951742 for Migraine Headache Prevention
A subcutaneously administered monoclonal antibody for prevention of frequent episodic migraine headache.
Entresto (Valsartan and Sacubitril) for Heart Failure
Entresto is a twice-daily valsartan and sacubitril combination pill to treat heart failure in patients with reduced ejection fraction. Entresto is also in development to treat heart failure in patients with preserved ejection fraction and to treat hypertension.
Orkambi (Kalydeco and Lumacaftor Combination Pill)
Orkambi is fixed-dose combination pill to treat cystic fibrosis in patients ≥ 12 years of age who are homozygous for the F508del mutation in the CFTR gene.
Lutonix 035 Drug-Coated Balloon (DCB) PTA Catheter
A drug-coated balloon PTA catheter to treat peripheral artery disease.
Afrezza (Insulin Human) Inhalation Powder
|
Manufacturer |
MannKind Corp. Sanofi has licensing agreement for global commercialization. |
||||
|
Hayes Viewpoint |
Afrezza is a rapid… Keytruda (Pembrolizumab) for Yervoy-Refractory Advanced Melanoma
|